Noticias de ABT_US

Mercado

Noticias del mercado

Últimas noticias sobre ABT_US — 735 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ABT_US ✕ 735 resultados
27/08/2026 ABT_US — Top Class Actions
Abbott Laboratories agrees to $670M settlement over premature infant formula claims
27/08/2026 ABT_US — MarketScreener
Abbott Laboratories' Stroke Treatment Device Receives CE Mark
27/08/2026 ABT_US — simplywall.st
Abbott Stock And Two Defensive Dividend Names For Uncertain Markets
27/08/2026 ABT_US — Medical Device and Diagnostic industry
Abbott Laboratories Obtains CE Mark for Amulet 360 LAA
27/08/2026 ABT_US — MarketWatch
Abbott Laboratories stock underperforms Thursday when compared to competitors
27/08/2026 ABT_US — Stock Titan
Abbott (NYSE: ABT) CEO sells 398K shares after option exercise
26/08/2026 ABT_US — The Daily Iowan
Iowa City Senior Center hosts inaugural blood drive before Abbott and Big Ten partnered “We Give Blood Drive”
26/08/2026 ABT_US — Courthouse News
Lawsuit accusing Abbott MitraClip of kickbacks will proceed
26/08/2026 ABT_US — Courthouse News
Lawsuit accusing Abbott MitraClip of kickbacks will proceed
26/08/2026 ABT_US — Crain's Chicago Business
Abbott scores FDA approval for first-of-its kind dual glucose sensor
26/08/2026 ABT_US — Reuters
Boston Scientific hit by cyberattack, global operations affected
26/08/2026 ABT_US — MarketScreener
Analyst recommendations: Nvidia, Intuit, BofA, Abbott Laboratories, Google…
26/08/2026 ABT_US — Benzinga
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
26/08/2026 ABT_US — Pasadena Now
Abbott, Big Ten Launch National “We Give Blood” Competition at the Rose Bowl Today

Daily Newsmagazine and City Guide to Pasadena, California featuring local news, breaking news, events, weather, sports news, schools news, shopping, restaurants and more from Pasadena Now

26/08/2026 ABT_US — simplywall.st
Why Is Abbott Laboratories (ABT) Launching A First Of Its Kind Diabetes Wearable?

Abbott Laboratories (NYSE:ABT) received FDA authorization for its Libre Duo 10 Day system, described as the world's first dual glucose ketone sensing biowearable for diabetes management. The Libre Duo 10 Day device is designed to continuously track both glucose and ketone levels to help address risks linked to diabetic ketoacidosis. Abbott plans a U.S. launch of Libre Duo 10 Day following the FDA authorization, adding a new offering to its digital health and diagnostics portfolio. Investors...

26/08/2026 ABT_US — Moomoo
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $118
26/08/2026 ABT_US — ChartMill
Abbott Laboratories (NYSE:ABT) Clears All Quality Investing Hurdles
26/08/2026 ABT_US — MarketScreener
FDA clears Abbott's first sensor to continuously measure glucose and ketones
26/08/2026 ABT_US — MarketWatch
Abbott Laboratories stock underperforms Wednesday when compared to competitors
26/08/2026 ABT_US — Yahoo Finance
What Does Abbott Laboratories (ABT) FDA Clearance Mean For Its Diabetes Device Push?

Página 3 de 37